[go: up one dir, main page]

MXPA03001983A - Exemestano como agente quimiopreventivo. - Google Patents

Exemestano como agente quimiopreventivo.

Info

Publication number
MXPA03001983A
MXPA03001983A MXPA03001983A MXPA03001983A MXPA03001983A MX PA03001983 A MXPA03001983 A MX PA03001983A MX PA03001983 A MXPA03001983 A MX PA03001983A MX PA03001983 A MXPA03001983 A MX PA03001983A MX PA03001983 A MXPA03001983 A MX PA03001983A
Authority
MX
Mexico
Prior art keywords
exemestane
chemopreventing
agent
chemopreventing agent
Prior art date
Application number
MXPA03001983A
Other languages
English (en)
Inventor
Dinesh Purandare
Original Assignee
Pharmacia Italia Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia Italia Spa filed Critical Pharmacia Italia Spa
Publication of MXPA03001983A publication Critical patent/MXPA03001983A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A61K31/5685—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone having an oxo group in position 17, e.g. androsterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/32—Antioestrogens

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
MXPA03001983A 2000-09-08 2001-08-31 Exemestano como agente quimiopreventivo. MXPA03001983A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US65805200A 2000-09-08 2000-09-08
PCT/EP2001/010172 WO2002020020A1 (en) 2000-09-08 2001-08-31 Exemestane as chemopreventing agent

Publications (1)

Publication Number Publication Date
MXPA03001983A true MXPA03001983A (es) 2003-06-24

Family

ID=24639711

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA03001983A MXPA03001983A (es) 2000-09-08 2001-08-31 Exemestano como agente quimiopreventivo.

Country Status (15)

Country Link
US (1) US20040024044A1 (es)
EP (1) EP1317270A1 (es)
JP (1) JP2004508334A (es)
KR (1) KR20030043955A (es)
CN (1) CN1729002A (es)
AR (1) AR034150A1 (es)
AU (2) AU8986501A (es)
BR (1) BR0113625A (es)
CA (1) CA2419590A1 (es)
MX (1) MXPA03001983A (es)
MY (1) MY137766A (es)
NZ (1) NZ524104A (es)
PE (1) PE20020348A1 (es)
WO (1) WO2002020020A1 (es)
ZA (1) ZA200301309B (es)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040053900A1 (en) * 1998-12-23 2004-03-18 Pharmacia Corporation Method of using a COX-2 inhibitor and an aromatase inhibitor as a combination therapy
GB0017635D0 (en) * 2000-07-18 2000-09-06 Pharmacia & Upjohn Spa Antitumor combined therapy
US6903121B1 (en) 2000-08-17 2005-06-07 Allergan, Inc. Treatment of tumors with acetylenes disubstituted with a phenyl or heteroaromatic group and a substituted chromanyl, thiochromanyl or tetrahydroquinolinyl group in combination with other anti-tumor agents
PL206142B1 (pl) * 2001-01-09 2010-07-30 Merck Patent Gmbhmerck Patent Gmbh Kompozycja i zestaw farmaceutyczny do leczenia nowotworów i przerzutów nowotworowych oraz ich zastosowanie
ES2269682T3 (es) * 2001-01-26 2007-04-01 Pfizer Italia S.R.L. Exemestano para tratar transtornos que dependen de hormonas.
DE10154464B4 (de) * 2001-11-08 2005-10-20 Max Delbrueck Centrum Oral verabreichbare pharmazeutische Zubereitung umfassend liposomal verkapseltes Taxol
JP4036885B2 (ja) 2003-09-19 2008-01-23 アストラゼネカ アクチボラグ キナゾリン誘導体
ZA200706247B (en) * 2005-02-09 2008-11-26 Genentech Inc Inhibiting HER2 shedding with matrix metalloprotease antagonists
CA2605796A1 (en) * 2005-04-25 2006-11-02 Pfizer Products Inc. Pharmaceutical compositions and methods comprising a combination of a selective estrogen receptor modulator and an aromatase inhibitor
CA2628747C (en) * 2005-11-22 2014-01-21 Incyte Corporation Combinations of hormone therapy agents and metalloprotease inhibitors for the treatment of cancer
PE20071043A1 (es) * 2006-02-14 2007-10-23 Wyeth Corp FORMULACIONES FARMACEUTICAS ACUOSAS QUE COMPRENDE LIGANDOS SELECTIVOS DEL RECEPTOR DE ESTROGENO ERß
KR20150050595A (ko) 2006-03-28 2015-05-08 자블린 파머슈티칼스 인코포레이티드 저 복용량의 디클로페낙 및 베타-사이클로덱스트린 제형
CA2647533A1 (en) * 2006-03-28 2007-10-04 Javelin Pharmaceuticals, Inc. Formulations of low dose non-steroidal anti-inflammatory drugs and beta-cyclodextrin
JP2009534462A (ja) * 2006-04-24 2009-09-24 パナセア バイオテック リミテッド ニメスリドを含有する新規な低用量医薬組成物、その調製および使用
WO2009042612A1 (en) * 2007-09-24 2009-04-02 Tragara Pharmaceuticals, Inc. Therapies for treating cancer using combinations of cox-2 inhibitors and aromatase inhibitors or combinations of cox-2 inhibitors and estrogen receptor antagonists
CN101468023B (zh) * 2007-12-26 2011-02-02 上海复星医药（集团）股份有限公司 依西美坦片及其制备工艺
KR100925811B1 (ko) * 2007-12-28 2009-11-06 주식회사 지에스메디칼 척추 고정기구
MX2012014431A (es) 2010-06-10 2013-02-26 Aragon Pharmaceuticals Inc Modulares del receptor de estrogenos y usos de los mismos.
EP2616078B1 (en) 2010-09-16 2019-12-25 Shimoda Biotech (Pty) Ltd Fulvestrant compositions and methods of use
JP2015500346A (ja) 2011-12-14 2015-01-05 セラゴン ファーマシューティカルズ，インク． エストロゲン受容体モジュレーターおよびその使用
EP3929196B1 (en) 2013-09-24 2023-08-23 FUJIFILM Corporation Pharmaceutical composition of a nitrogen-containing compound or salt thereof, or metal complex thereof
CN108779077A (zh) 2015-12-30 2018-11-09 圣路易斯大学 作为pan整合素拮抗剂的间位氮杂环氨基苯甲酸衍生物
TWI639430B (zh) * 2016-08-27 2018-11-01 中國醫藥大學 醫藥組合物用於製備治療胃癌藥物的用途
WO2021142083A1 (en) * 2020-01-10 2021-07-15 Takeda Pharmaceutical Company Limited A method for enhancing the pharmacokinetics or increasing the plasma concentration of methyl 3-((methylsulfonyl)amino)-2-(((4-phenylcyclohexyl)oxy)methyl)piperidine-1-carboxylate or a salt thereof with an inhibitor of cytochrome p450
WO2023178035A1 (en) 2022-03-14 2023-09-21 Slap Pharmaceuticals Llc Multicyclic compounds
CN114948901B (zh) * 2022-05-06 2023-04-21 郑州大学第一附属医院 一种协同治疗乳腺癌的依西美坦纳米粒、制剂及其制备方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8517360D0 (en) * 1985-07-09 1985-08-14 Erba Farmitalia Substituted androsta-1,4-diene-3,17-diones
AUPN814496A0 (en) * 1996-02-19 1996-03-14 Monash University Dermal penetration enhancer
PL350291A1 (en) * 1998-12-23 2002-12-02 Searle & Co Method of using a cyclooxygenase-2 inhibitor and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia
GB9911582D0 (en) * 1999-05-18 1999-07-21 Pharmacia & Upjohn Spa Combined method of treatment comprising an aromatase inhibitor and a further biologically active compound
GB0005257D0 (en) * 2000-03-03 2000-04-26 Pharmacia & Upjohn Spa Breast cancer hormonal therapy

Also Published As

Publication number Publication date
MY137766A (en) 2009-03-31
ZA200301309B (en) 2004-02-18
AU2001289865B2 (en) 2007-03-01
CN1729002A (zh) 2006-02-01
CA2419590A1 (en) 2002-03-14
AR034150A1 (es) 2004-02-04
WO2002020020A1 (en) 2002-03-14
US20040024044A1 (en) 2004-02-05
PE20020348A1 (es) 2002-04-18
BR0113625A (pt) 2003-07-22
KR20030043955A (ko) 2003-06-02
NZ524104A (en) 2004-12-24
EP1317270A1 (en) 2003-06-11
JP2004508334A (ja) 2004-03-18
AU8986501A (en) 2002-03-22

Similar Documents

Publication Publication Date Title
MXPA03001983A (es) Exemestano como agente quimiopreventivo.
ZA200204165B (en) Fulvestrant formulation.
EG24742A (en) Vaccine composition.
MXPA03002410A (es) 4-amino-quinazolinas.
ZA200300793B (en) Substituted-triazolopyrimidines as anticancer agents.
ZA200205479B (en) Novel biarylcarboxamides.
MXPA03005445A (es) Barra colectora 12c para aislar los circuitos integrados seleccionados para una comunicacion rapida de barra colectora 12c.
ZA200205528B (en) Glyburide composition.
EP1315094A4 (en) AGENT SYSTEM
EG23262A (en) Delta -pyrrolines.
MXPA03003522A (es) Panal.
EP1151667A3 (en) Plant-activating agent
MXPA03000107A (es) Pirroloquinolonas como agentes antivirales.
MXPA03007693A (es) Composicion para la piel.
AU6807501A (en) 1-aryl-4-oxo-1,4-dihydro-3-quinolinecarboxamides as antiviral agents
MXPA03001591A (es) Derivados y analogos de 10-aril-11-h-benzo(b) fluorena para uso medicinal.
MXPA03001877A (es) 2-guanidin-4-arilquinazolinas.
MXPA03007314A (es) Composicion para la piel para reducir aceites y grasa de la piel.
MXPA03002668A (es) Guanidinas de sulfonilo.
MXPA03001991A (es) Novedosas arilalcano-sulfonamidas.
MXPA03005714A (es) Sulfamidotienopirimidinas.
MXPA03002411A (es) 4-amino-quinazolinas.
EG23378A (en) Composition.
GB0302803D0 (en) Not available
MXPA03005494A (es) Benzoilpiridazinas.

Legal Events

Date Code Title Description
FA Abandonment or withdrawal